Page 18«..10..17181920..3040..»

Category Archives: MS Treatment

A vision of a world free from the effects of multiple sclerosis – Open Access Government

Posted: Published on November 22nd, 2020

Over 130,000 people live with multiple sclerosis (MS) in the UK, and a diagnosis can have a profound impact. Continue reading

Posted in MS Treatment | Comments Off on A vision of a world free from the effects of multiple sclerosis – Open Access Government

Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis? – DocWire News

Posted: Published on November 22nd, 2020

Recent Pat Drug Deliv Formul. 2020 Nov 17. doi: 10.2174/1872211314999201117130123 Continue reading

Posted in MS Treatment | Comments Off on Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis? – DocWire News

Early Treatment Improvements in Depression Are Associated With Overall Improvements in Fatigue Impact and Pain Interference in Adults With Multiple…

Posted: Published on November 22nd, 2020

This article was originally published here Ann Behav Med. 2020 Nov 16:kaaa102. doi: 10.1093/abm/kaaa102 Continue reading

Posted in MS Treatment | Comments Off on Early Treatment Improvements in Depression Are Associated With Overall Improvements in Fatigue Impact and Pain Interference in Adults With Multiple…

Officials: New COVID-19 cases shifting toward younger Mississippians; vaccines on the way – Clarion Ledger

Posted: Published on November 22nd, 2020

More promising news on the vaccine front: Moderna says its vaccine provides strong protection against COVID-19. Continue reading

Posted in MS Treatment | Comments Off on Officials: New COVID-19 cases shifting toward younger Mississippians; vaccines on the way – Clarion Ledger

GW Pharma shares rally on earnings and news of late-stage trial of cannabis-based treatment for MS patients – MarketWatch

Posted: Published on November 9th, 2020

Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabinoid-based treatment for multiple sclerosis spasticity can now proceed. Volume of 2.14 million shares traded was 5.5 times the 65-day average of 385,930. GW Pharma GWPH, +2.41% is the first company to win U.S. Continue reading

Posted in MS Treatment | Comments Off on GW Pharma shares rally on earnings and news of late-stage trial of cannabis-based treatment for MS patients – MarketWatch

Hydroxychloroquine does not benefit adults hospitalized with COVID-19 – National Institutes of Health

Posted: Published on November 9th, 2020

News Release Monday, November 9, 2020 A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was stopped indicated that the drug was not improving outcomes in COVID-19 patients Continue reading

Posted in MS Treatment | Comments Off on Hydroxychloroquine does not benefit adults hospitalized with COVID-19 – National Institutes of Health

Informative video series launched to support people living with secondary progressive MS – Offaly Express

Posted: Published on November 9th, 2020

MS Ireland and Novartis have launched a new video series entitled SPMS Explained,which aims to support those living with secondary progressive multiple sclerosis (SPMS) in Ireland. People with SPMS are typically diagnosed after 10 to 20 years living with relapsing remitting MS (RRMS) and studies indicate that 50% of those diagnosed with RRMS will transition to SPMS within 10 years, and 90% will transition within 25 years. SPMS symptoms do not go away completely after a relapse or flare-up and there is a steady increase in disability Continue reading

Posted in MS Treatment | Comments Off on Informative video series launched to support people living with secondary progressive MS – Offaly Express

Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics – PR Newswire India

Posted: Published on November 9th, 2020

Not intended for UK and US based media -Merck out-licenses Phase IIb-ready atacicept to Vera Therapeutics - Phase IIa trial conducted by Merck shows promising results in IgA nephropathy (IgAN), also known as "Berger's disease" - Out-licencing deal includes 10% equity in Vera Therapeutics and up to 605 million in development and commercial milestones, plus royalties on any future net sales DARMSTADT, Germany, Nov. Continue reading

Posted in MS Treatment | Comments Off on Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics – PR Newswire India

Therapeutic Role of Inflammasome Inhibitors in Neurodegenerative Disorders – DocWire News

Posted: Published on November 9th, 2020

This article was originally published here Brain Behav Immun. 2020 Nov 3:S0889-1591(20)32378-3. doi: 10.1016/j.bbi.2020.11.004. Continue reading

Posted in MS Treatment | Comments Off on Therapeutic Role of Inflammasome Inhibitors in Neurodegenerative Disorders – DocWire News

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS – DocWire News

Posted: Published on November 9th, 2020

This article was originally published here BMC Med. 2020 Nov 4;18(1):298. doi: 10.1186/s12916-020-01769-6. Continue reading

Posted in MS Treatment | Comments Off on Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS – DocWire News

Page 18«..10..17181920..3040..»